



Eduardo Pisani
Director General
IFPMA
Ch. Louis-Dunant 15 P.O. Box 195
1211 Geneva 20, Switzerland

Paris, November 7th, 2014

Dear Mr Pisani,

With reference to your letter dated 30 October 2014 informing us of the IFPMA's Ad-hoc Appeal Group decision (Code Complaint reference C2013-03), please find below the Sanofi Compliance Statement to be published with the summary of the case on the IFPMA's website on 14 November 2014.

Sanofi is committed to conduct its business with the highest standards of ethics and integrity. The item of medical utility in question (blood pressure monitor) has been distributed to pharmacies to support them in providing medical-related service for the benefit of the patients. In all good faith, and considering usual practices in Egypt, Sanofi did consider that the price of this item (blood pressure monitor) was of modest value according to the IFPMA Code section 7.5.3. Although Sanofi believes that the ruled breach is overstated when taking into consideration the country economic context and the normal market practice in Egypt, yet, Sanofi confirms, with immediate effect, that the blood pressure monitor in question will no longer be distributed to pharmacies. In the future, Sanofi will be mindful of this IFPMA decision when assessing the value of item of medical utility.

I remain available should you have any question.

Best regards

A handwritten signature in blue ink, appearing to read "Dante Beccaria".

Dante Beccaria
Global Compliance Officer
Head Global Compliance & Business Integrity Department